The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis

Julie Ahn, Justin A. Bishop, Richard B.S. Roden, Clint T. Allen, Simon R.A. Best

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives/Hypothesis: Generation of an immunosuppressive microenvironment may enable a persistent human papillomavirus infection in the setting of an otherwise normal immune system. We hypothesized that expression of the T-lymphocyte co-inhibitory receptor programmed death 1 (PD-1) and its ligand PD-L1 would be increased in the recurrent respiratory papillomatosis (RRP) microenvironment compared to normal controls. Study Design: Case-control study. Methods: Formalin-fixed paraffin-embedded respiratory papilloma and normal controls were obtained under institutional review board approval, stained for CD4, CD8, FoxP3, and PD-1, and scored by automated cell count. PD-L1 staining was scored by a blinded pathologist using an adjusted inflammation score that accounted for epithelial and immune infiltrate. Results: Thirty-nine RRP cases and seven controls were studied. All immunologic markers demonstrated significantly increased staining in RRP specimens compared to normal controls (all P <.01). PD-1 correlated with both CD4 (P <.0001) and CD8 (P <.001) cell counts. Epithelial staining for PD-L1 (68%) and PD-L1+ infiltrating immune cells (76%) were observed in the majority of papilloma samples. The strongest staining for PD-L1 was usually observed in the basal papilloma layer adjacent to the immunologic infiltrate in the vascular core. Disease severity inversely correlated with CD8 cell counts (P =.01). A correlation between disease severity and other immunologic markers was not observed. Conclusions: Most RRP specimens demonstrate PD-1 T-lymphocyte infiltration and PD-L1 expression on both papilloma and infiltrating immune cells. This study suggests that this checkpoint pathway may be contributing to local immunosuppression in RRP, and opens the door for clinical trials utilizing PD-blocking monoclonal antibodies. Level of Evidence: NA Laryngoscope, 128:E27–E32, 2018.

Original languageEnglish (US)
Pages (from-to)E27-E32
JournalLaryngoscope
Volume128
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Papilloma
Staining and Labeling
Cell Count
Costimulatory and Inhibitory T-Cell Receptors
Biomarkers
Laryngoscopes
Blocking Antibodies
Papillomavirus Infections
Research Ethics Committees
Immunosuppressive Agents
Paraffin
Immunosuppression
Formaldehyde
Blood Vessels
Case-Control Studies
Immune System
Monoclonal Antibodies
Recurrent respiratory papillomatosis
Clinical Trials
Ligands

Keywords

  • human papillomavirus
  • laryngeal papilloma
  • programmed death
  • Recurrent respiratory papillomatosis

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Ahn, J., Bishop, J. A., Roden, R. B. S., Allen, C. T., & Best, S. R. A. (2018). The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis. Laryngoscope, 128(1), E27-E32. https://doi.org/10.1002/lary.26847

The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis. / Ahn, Julie; Bishop, Justin A.; Roden, Richard B.S.; Allen, Clint T.; Best, Simon R.A.

In: Laryngoscope, Vol. 128, No. 1, 01.01.2018, p. E27-E32.

Research output: Contribution to journalArticle

Ahn, J, Bishop, JA, Roden, RBS, Allen, CT & Best, SRA 2018, 'The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis', Laryngoscope, vol. 128, no. 1, pp. E27-E32. https://doi.org/10.1002/lary.26847
Ahn, Julie ; Bishop, Justin A. ; Roden, Richard B.S. ; Allen, Clint T. ; Best, Simon R.A. / The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis. In: Laryngoscope. 2018 ; Vol. 128, No. 1. pp. E27-E32.
@article{0b9a3d1019cb4548b2df978f4cb7bf64,
title = "The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis",
abstract = "Objectives/Hypothesis: Generation of an immunosuppressive microenvironment may enable a persistent human papillomavirus infection in the setting of an otherwise normal immune system. We hypothesized that expression of the T-lymphocyte co-inhibitory receptor programmed death 1 (PD-1) and its ligand PD-L1 would be increased in the recurrent respiratory papillomatosis (RRP) microenvironment compared to normal controls. Study Design: Case-control study. Methods: Formalin-fixed paraffin-embedded respiratory papilloma and normal controls were obtained under institutional review board approval, stained for CD4, CD8, FoxP3, and PD-1, and scored by automated cell count. PD-L1 staining was scored by a blinded pathologist using an adjusted inflammation score that accounted for epithelial and immune infiltrate. Results: Thirty-nine RRP cases and seven controls were studied. All immunologic markers demonstrated significantly increased staining in RRP specimens compared to normal controls (all P <.01). PD-1 correlated with both CD4 (P <.0001) and CD8 (P <.001) cell counts. Epithelial staining for PD-L1 (68{\%}) and PD-L1+ infiltrating immune cells (76{\%}) were observed in the majority of papilloma samples. The strongest staining for PD-L1 was usually observed in the basal papilloma layer adjacent to the immunologic infiltrate in the vascular core. Disease severity inversely correlated with CD8 cell counts (P =.01). A correlation between disease severity and other immunologic markers was not observed. Conclusions: Most RRP specimens demonstrate PD-1 T-lymphocyte infiltration and PD-L1 expression on both papilloma and infiltrating immune cells. This study suggests that this checkpoint pathway may be contributing to local immunosuppression in RRP, and opens the door for clinical trials utilizing PD-blocking monoclonal antibodies. Level of Evidence: NA Laryngoscope, 128:E27–E32, 2018.",
keywords = "human papillomavirus, laryngeal papilloma, programmed death, Recurrent respiratory papillomatosis",
author = "Julie Ahn and Bishop, {Justin A.} and Roden, {Richard B.S.} and Allen, {Clint T.} and Best, {Simon R.A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/lary.26847",
language = "English (US)",
volume = "128",
pages = "E27--E32",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis

AU - Ahn, Julie

AU - Bishop, Justin A.

AU - Roden, Richard B.S.

AU - Allen, Clint T.

AU - Best, Simon R.A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objectives/Hypothesis: Generation of an immunosuppressive microenvironment may enable a persistent human papillomavirus infection in the setting of an otherwise normal immune system. We hypothesized that expression of the T-lymphocyte co-inhibitory receptor programmed death 1 (PD-1) and its ligand PD-L1 would be increased in the recurrent respiratory papillomatosis (RRP) microenvironment compared to normal controls. Study Design: Case-control study. Methods: Formalin-fixed paraffin-embedded respiratory papilloma and normal controls were obtained under institutional review board approval, stained for CD4, CD8, FoxP3, and PD-1, and scored by automated cell count. PD-L1 staining was scored by a blinded pathologist using an adjusted inflammation score that accounted for epithelial and immune infiltrate. Results: Thirty-nine RRP cases and seven controls were studied. All immunologic markers demonstrated significantly increased staining in RRP specimens compared to normal controls (all P <.01). PD-1 correlated with both CD4 (P <.0001) and CD8 (P <.001) cell counts. Epithelial staining for PD-L1 (68%) and PD-L1+ infiltrating immune cells (76%) were observed in the majority of papilloma samples. The strongest staining for PD-L1 was usually observed in the basal papilloma layer adjacent to the immunologic infiltrate in the vascular core. Disease severity inversely correlated with CD8 cell counts (P =.01). A correlation between disease severity and other immunologic markers was not observed. Conclusions: Most RRP specimens demonstrate PD-1 T-lymphocyte infiltration and PD-L1 expression on both papilloma and infiltrating immune cells. This study suggests that this checkpoint pathway may be contributing to local immunosuppression in RRP, and opens the door for clinical trials utilizing PD-blocking monoclonal antibodies. Level of Evidence: NA Laryngoscope, 128:E27–E32, 2018.

AB - Objectives/Hypothesis: Generation of an immunosuppressive microenvironment may enable a persistent human papillomavirus infection in the setting of an otherwise normal immune system. We hypothesized that expression of the T-lymphocyte co-inhibitory receptor programmed death 1 (PD-1) and its ligand PD-L1 would be increased in the recurrent respiratory papillomatosis (RRP) microenvironment compared to normal controls. Study Design: Case-control study. Methods: Formalin-fixed paraffin-embedded respiratory papilloma and normal controls were obtained under institutional review board approval, stained for CD4, CD8, FoxP3, and PD-1, and scored by automated cell count. PD-L1 staining was scored by a blinded pathologist using an adjusted inflammation score that accounted for epithelial and immune infiltrate. Results: Thirty-nine RRP cases and seven controls were studied. All immunologic markers demonstrated significantly increased staining in RRP specimens compared to normal controls (all P <.01). PD-1 correlated with both CD4 (P <.0001) and CD8 (P <.001) cell counts. Epithelial staining for PD-L1 (68%) and PD-L1+ infiltrating immune cells (76%) were observed in the majority of papilloma samples. The strongest staining for PD-L1 was usually observed in the basal papilloma layer adjacent to the immunologic infiltrate in the vascular core. Disease severity inversely correlated with CD8 cell counts (P =.01). A correlation between disease severity and other immunologic markers was not observed. Conclusions: Most RRP specimens demonstrate PD-1 T-lymphocyte infiltration and PD-L1 expression on both papilloma and infiltrating immune cells. This study suggests that this checkpoint pathway may be contributing to local immunosuppression in RRP, and opens the door for clinical trials utilizing PD-blocking monoclonal antibodies. Level of Evidence: NA Laryngoscope, 128:E27–E32, 2018.

KW - human papillomavirus

KW - laryngeal papilloma

KW - programmed death

KW - Recurrent respiratory papillomatosis

UR - http://www.scopus.com/inward/record.url?scp=85038415183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038415183&partnerID=8YFLogxK

U2 - 10.1002/lary.26847

DO - 10.1002/lary.26847

M3 - Article

C2 - 28940446

AN - SCOPUS:85038415183

VL - 128

SP - E27-E32

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 1

ER -